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Background: Universal screening using the International Association of Diabetes and Pregnancy Study Groups
(IADPSG) criteria has identified a prevalence of gestational diabetes mellitus (GDM) of 12.4% in women living in
Ireland. Women with prior GDM are at increased risk of developing type 2 diabetes later in life. A number of risk
factors linked to the development of type 2 diabetes are potentially modifiable through lifestyle and behaviour
changes, and medical management. No previous Irish studies have adequately investigated the efficacy of lifestyle
intervention programmes in reducing these risk factors in women with prior GDM. Through a two-group, parallel
randomised controlled trial (RCT), this study aims to assess the clinical impact, cost-effectiveness and psychological
experience of the Croí MyAction intensive lifestyle modification programme for women with prior GDM.
Methods/Design: A total of 54 women with a history of GDM and persistent post-partum glucose dysfunction
(impaired glucose tolerance (IGT) or impaired fasting glucose (IFG)), are randomly assigned to a control arm (n = 27) or
to the Croí MyAction intervention group (n = 27). The control arm receives usual health care advice - written
information on diet and lifestyle changes for reducing diabetes risks and visits with general practitioners as required.
The intervention group receives usual health care as per the control group in addition to attending a 12-week
intensive lifestyle modification programme known as Croí MyAction. Croí MyAction involves 2.5 hour sessions once per
week (for 12 weeks) comprising a group exercise programme, group health promotion or education seminars, and
one-to-one meetings with a multidisciplinary health care team to personalise risk factor reductions. Randomisation and
allocation to the intervention arms is carried out by an independent researcher, ensuring that the allocation sequence
is concealed from study researchers until the interventions are assigned. The primary analysis is based on glucose
dysfunction, comparing a mean reduction in fasting plasma glucose (FPG) levels on a 75 gram oral glucose tolerance
test (OGTT) in the two groups at a one-year, post-intervention follow-up. The trial is funded by the Irish Health
Research Board (HRB). Ethics approval was obtained on 27 March 2012 from the Clinical Research Ethics Committee,
Galway University Hospitals, Health Service Executive of Ireland (Ref: C.A.691).
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Gestational diabetes mellitus (GDM) is defined as any
degree of glucose intolerance resulting in hyperglycaemia,
or excess sugar, in a mother’s blood during pregnancy [1].
When present, the pregnancy may be associated with a
number of adverse maternal and neonatal outcomes.
Neonatal complications include hypoglycaemia respiratory
distress syndrome and jaundice, and macrosomia may
result in shoulder dystocia [2-5]. Adverse maternal out-
comes include pregnancy induced hypertension (PIH),
pre-eclampsia toxaemia (PET), polyhydramnios and an
increased risk of delivery by caesarian section [2,4-6].
GDM is also associated with increased psychological stress
during pregnancy [7]. Later in life, both the mother and
child are at increased risk of hospital admission, obesity,
type 2 diabetes and heart disease [8-14].
There is a paucity of robust evidence relating to the
prevalence of GDM in the international literature [15].
Prevalence estimates have been complicated by the wide
range of definitions and test criteria used for diagnosing
GDM and vary according to region and ethnic group
[16]. There is a general consensus, however, that the
prevalence of GDM is increasing globally and occurs in
approximately 2 to 9% of all pregnancies [6,17]. Several
factors have been shown to be associated with an
increased risk of GDM. Increasing age, previous GDM,
pre-pregnancy obesity, a previous macrosomic baby
(larger than 4.5 kg), a family history of diabetes (amongst
first-degree relatives), and particular ethnic origins are
generally accepted as risk factors [16]. In Ireland, accurate
and up-to-date data on the incidence of hyperglycaemia in
pregnancy were lacking prior to 2007, when the first
results of the Atlantic Diabetes in Pregnancy (DIP)
research programme were published. The Atlantic DIP
programme, funded between 2005 and 2010 by Ireland’s
Health Research Board, found that at least 12% of preg-
nancies are complicated by GDM in Ireland [3]. In
addition, approximately 18% of these women suffered
from persistent post-partum glucose abnormalities in the
first year following the birth, compared to 2% in women
with proven normal glucose tolerance (NGT) in the index
pregnancy, during the same time and accessing the same
health care services in the same geographical location
[13]. These glucose abnormalities included type 2 dia-
betes, but also IFG, IGT, metabolic syndrome (MetS) and
insulin resistance (IR), conditions recognised as interme-
diary stages in the development of type 2 diabetes.Diabetes is associated with significant morbidity and
mortality and is one of the fastest growing chronic
health conditions in Ireland and worldwide. Some of the
biological risk factors associated with the development
of type 2 diabetes are non-modifiable, such as age, ethni-
city or family history of the disease. However, there are a
range of risk factors that are potentially modifiable
through lifestyle changes, for example, central adiposity,
elevated fasting blood sugars, triglycerides or blood pres-
sure; behavioural factors, such as poor diet or sedentary
lifestyle; and a host of cognitive and mood factors which
delimit or facilitate healthy lifestyle changes (self-efficacy,
motivation to change, depression or anxiety) [18]. A
growing body of research suggests that “for people with
pre-diabetes, weight loss and therefore reduction in body
mass index (BMI) and waist circumference [alone] is
successful in reducing the risk of developing diabetes”
[18]. Saaristo et al. (2010) found that modest weight loss
(circa 5%) in a community care setting is especially effec-
tive in reducing risk of diabetes [19].
With this evidence, randomised clinical trials in a
number of countries have investigated the effects of life-
style interventions in high risk groups, including women
with prior GDM, on the reduction of progression to type
2 diabetes [18,20-23]. These studies have shown that
type 2 diabetes can be prevented, or at least postponed,
by even modest lifestyle changes. In Ireland, no previous
research has adequately evaluated the outcomes of life-
style intervention for this cohort of women. Without
such research, we are left with an inadequate analysis of
the efficacy of lifestyle intervention programmes for
delaying diabetes onset in women with prior GDM in
Ireland. It is also unclear whether participation in such
interventions can help women sustain improvements in
lifestyle practices, such as diet and physical activity, over
time (that is, when the intervention is over). This study
seeks to remedy this gap through the development of a
randomised controlled trial (RCT) which will evaluate
the effectiveness of Croí MyAction, an intensive 12-week
lifestyle intervention programme, as compared with
standard health care provided to women with a history
of GDM. The trial will compare the two study arms in
terms of a mean reduction in fasting blood glucose dys-
function from the time of a baseline assessment to a
one-year follow-up.
Croí is the West of Ireland Cardiac Foundation. Croí
MyAction is a lifestyle and risk factor modification
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diovascular disease. It is the only initiative of its kind in
the country that integrates the care of patients at high
risk of cardiovascular diseases and type 2 diabetes in a
community-based setting. Croí MyAction was developed
in collaboration with the Irish Health Service Executive
(HSE) and Imperial College London. The 12-week inter-
vention programme is modeled on the European Society
of Cardiology demonstration project, a large clinical trial
called EuroAction. EuroAction was a cluster RCT of a
preventive cardiology intervention programme in Europe.
It demonstrated that nurse-managed, multi-disciplinary,
family-based programmes could achieve healthier lifestyle
changes and better risk factor control than usual care at
the time of a one-year follow-up [24]. The 12-week Croí
MyAction programme in Ireland incorporates the prin-
ciples and protocols of EuroAction. It is delivered by a
multidisciplinary team of nurses, dieticians, physiothe-
rapists and physical activity specialists, supported by a
physician. It is family-centered, encouraging patients to
participate in the programme with a partner. The
emphasis of Croí MyAction is on healthy lifestyle change
aimed at improving quality and enjoyment of life; for
example, empowering individuals and families to make
sustainable changes through behavioural approaches, such
as motivational interviewing and goal-setting. The pro-
gramme includes management of blood pressure, lipids,
glucose and adherence with cardio-protective medications;
finally, it is community-based, thus increasing its
accessibility.
While this model of prevention has been evaluated
through the EuroAction study, it has not been assessed
in women with prior GDM. In this study, therefore, the
effectiveness of the Croí MyAction programme will be
measured in terms of a reduction in the modifiable
biomedical, anthropometric and psychosocial risk factors
associated with the development of type 2 diabetes in
women with prior GDM. In addition, following the RCT,
qualitative methods will be used to examine participants’
experiences of the Croí MyAction intervention prog-
ramme in terms of its feasibility and perceived strengths
and weaknesses. Finally, an economic evaluation will be
undertaken to explore the cost-effectiveness of the
programme. This integrative, multidisciplinary approach -
incorporating clinical, psychological and economic eva-
luations - is expected to make novel contributions to
knowledge in the field of diabetes research.
Methods/Design
Setting
The study takes place along the Irish Atlantic seaboard,
which extends from the north-western corner of Ireland
through the west coast and islands, to the city of Galway.
The coordinating centre is the School of Medicine at theNational University of Ireland, Galway (NUI Galway),
involving the academic departments of medicine, obstet-
rics, general practice, economics and psychology. The
intervention programme is delivered by Croí–West of
Ireland Cardiac Foundation, a community-based organisa-
tion also located in Galway. All data collection, including
the baseline tests, the Croí MyAction intervention
programme, and the one-year follow-up tests, occur in a
community setting. Ethics approval for the study was
obtained in March 2012 from the Clinical Research Ethics
Committee of Galway University Hospital, part of Ireland’s
Health Service Executive (HSE).
Hypothesis
The formal null hypothesis to be tested in this study is
that there is no difference in mean reduction in glucose
dysfunction amongst the population of women with
prior GDM following participation in Croí MyAction
when compared with women receiving usual health care.
The alternative hypothesis is that the Croí MyAction
group will show significantly better outcomes than
women receiving usual care.
Sample size and power calculation
The sample size required for the RCT is 54 participants.
This number was calculated based on estimates provided
from pilot data from a group of women with a history of
GDM (n = 74) receiving conventional health care. The
pilot group had a standard deviation of 0.64 mmol/l for
the difference in fasting plasma glucose (FPG) on an oral
glucose tolerance test between two time points: approxi-
mately three months post-pregnancy and then one to
three years later. Given the standard deviation, it is
estimated that a sample size of 27 in each study arm is
necessary to have 80% power to detect a mean difference
of 0.5 mmol/l in FPG between baseline and one-year
follow-up in the two study arms, using a two-sample
t-test at the 0.05 significance level.
Participants: recruitment and eligibility
Potential participants are identified from the Atlantic
Diabetes in Pregnancy (DIP) research database and the
pregnancy service of the Diabetes Day Centre at the
University Hospital Galway. These women are sent
invitation letters and research study information leaflets
in the post. The mail-outs are then followed by phone
calls from the study researchers to determine interest in
the study (that is, obtain verbal consent), answer any
questions about the study, and schedule appointments
for baseline health assessments over the following
month. On the baseline assessment days, the researchers
obtain written, informed consent from each participant
and administer a series of clinical, anthropometric,
behavioural and psychological tests, measures and
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come measures of the trial. The recruitment process is
anticipated to span 10 months, from June 2012 to March
2013. The flow chart in Figure 1 represents the move-
ment of a participant through the stages of recruitment
to the study.
Following the baseline health assessments, eligibility
for the study is determined on the following criteria:
Inclusion criteria
Participants are women of child-bearing age, 18 years
and older, with a history of GDM. At the time of recruit-
ment, they also show at least one of the following dia-
betes risk factors:
1. Impaired fasting glucose (fasting plasma glucose
levels of >5.6 <7 mmol/la); or
2. Impaired glucose tolerance (two-hour plasma
glucose levels of >7.8 <11.1 mmol/l); or
3. Insulin resistance based on homeostasis model
assessment (HOMA) plus two of the following risk
factors: (a) blood pressure > 130/80 mmHG, (b)
total cholesterol >4.5 mmol/l, (c) LDL cholesterol
>2.5 mmol/l, (d) triglycerides >1.69 mmol/l, (e) HDL
cholesterol >1.29 mmol/l, (f ) obesity (defined as
BMI >30), (g) waist circumference >88 cm.
Exclusion criteria
At the time of recruitment, individuals who have any of
the following are not eligible to participate in the study:
(i) developed type 2 diabetes mellitus; (ii) are currently
pregnant; (iii) have inadequate English language ability to
understand the content of the intervention programme;
or (iv) have significant cognitive impairment or mental
illness.
Randomisation process
The randomisation process in this RCT will use random
permuted blocks to ensure similar numbers of partici-
pants in each intervention arm throughout the trial and
equal numbers in each arm by the end of the study. In
advance of participant recruitment, an independent
researcher is responsible for generating the allocation
sequence using the free computer software program,
Random Allocation Software (version 1.0.0), M. Saghaei,
Isfahan University of Medical Sciences, Isfahan, Iran.
The same independent researcher is responsible for
assigning participants to the intervention groups. Thus,
the allocation sequence is concealed from all study
researchers until the interventions are assigned.
Description of interventions/comparison groups
The study is a two-group, parallel randomised controlled
trial. As such, following the baseline assessments, eligibleparticipants are randomly assigned to the intervention
and control groups in an equal ratio of 1:1. Those
assigned to the intervention group receive the 12-week
intensive lifestyle programme, Croí MyAction. The
programme includes an initial individualised assessment
by the multidisciplinary health care team, followed by 12
sessions of 2.5 hours each per week (delivered in a ma-
ximum of 16 weeksb). Each of the weekly sessions com-
prises a one-hour group exercise programme, a group
health promotion and education seminar, and one-to-one
meetings to review individual health goals with a specialist
nurse, physiotherapist and dietician. As previously men-
tioned, each Croí MyAction participant is invited to enroll
a family member, spouse, friend or other partner in the
programme with them for support and motivation outside
the programme hours. The intervention is conducted in
groups of similar sizes on the same site with the same facil-
itators, thus ensuring standardised delivery.
The control group receives the standard health care
advice provided to women with prior GDM. In this
study, standard care is defined as: (i) the provision of
educational pamphlets for reducing diabetes risks - par-
ticularly, healthy eating and regular physical activity; and
(ii) care prescribed by a woman’s general practitioner
(GP) as required. It is recognised that GP care will vary
from individual to individual.
Outcomes
The primary outcome measure in the study is glucose
dysfunction, which will be assessed in terms of a mean
reduction in fasting plasma glucose levels from the time
of the baseline assessment to the one-year follow-up
assessment, on a 75 gram oral glucose tolerance test.
Seven secondary outcomes will also be measured at the
baseline and one-year follow-up assessments; namely:
two-hour postprandial (PP) blood glucose levels on a 75
gram OGTT, insulin resistance, diet adherence, weight
and shape, physical activity and fitness, lipid profile, and
psychological evaluation. For participants in the Croí
MyAction arm of the study, a number of these outcomes
will also be measured immediately following the inter-
vention. Table 1 outlines the definitions, measurement




All participants will be invited back for one-year follow-
up tests to evaluate the effects of the Croí MyAction
programme on the same biomedical, anthropometric
and psychological measures administered at the baseline
assessment. These quantitative data will be analysed in a
variety of ways, focusing on comparisons within individual
participants (that is, before and after the intervention) and
Table 1 Secondary outcomes: definitions and measurement techniques





1 Postprandial glucose dysfunction Mean reduction in two-hour postprandial (PP)
blood glucose on a 75 gram oral glucose tolerance
test (OGTT)
✓ ✓
2 Insulin resistance Decrease in insulin resistance as measured by
Homeostasis Model Assessment (HOMA) on insulin
and glucose values on a 75 gram OGTT
✓ ✓
3 Diet adherence Two-point improvement in overall MedDietScore - a
composite diet index based on the traditional
Mediterranean dietary pattern
✓ ✓ ✓
4 Weight and shape a. Mean weight reduction (kilograms) in individuals
with a Body Mass Index (BMI) of >30 kg/m2 at
baseline; and
✓ ✓ ✓
b. Mean reduction in waist circumference in
individuals with a measurement of >88 cm at
baseline
5 Physical activity and fitness a. Proportions meeting physical activity target of at
least 30 minutes of moderate intensity aerobic
activity on at least five days of the week; and
✓ ✓ ✓
b. Change in functional capacity on an objective
physical fitness test (Chester Step Test or six-minute
walk test), estimated in metabolic equivalents (METs)
or time on test
6 Lipid profile a. Proportions achieving a lipid target profile of the
following values: total cholesterol <4.5 mmol/l, LDL
cholesterol <2.5 mmol/l, triglycerides <1.69 mmol/l,
HDL cholesterol >1.29 mmol/l; and
✓ ✓ ✓
b. Mean reduction in total and LDL cholesterol
7 Psychological evaluation (including: positive
mental health; general health; quality of life;
perceived social support; motivation to change;
diabetes-related self-efficacy; depression, anxiety
and stress)
a. Positive mental health: four-items from RAND SF-36
questionnaire addressing affective aspects of well-
being and five-items from the Mental Health Index-5
(MHI-5) in the RAND SF-36 questionnaire on the
occurrence and extent of non-specific psychological
distress
✓ ✓
b. General health: Stand-alone measure of self-rated
health included in the Irish Survey of Lifestyle,
Attitudes and Nutrition (SLÁN), 2007 (originally from
The Healthy Days Measures (HRQOL-4))
c. Quality of life: Single-item assessment included in
SLÁN 2007 (originally from the World Health
Organization’s Quality of Life Survey (WHO-QOL
Group, 1998))
d. Perceived social support: Multidimensional Scale of
Perceived Social Support from family, friends, and a
significant other (Zimet, Dahlem, Zimet and Farley, 1988)
e. Motivation to change: Moore et al.’s (2011) scale
developed for Australian randomised controlled trial on
a lifestyle intervention programme to prevent type 2
diabetes (based on Prochaska et al.’s (1992)
identification of various stages in relation to maintaining
a healthier lifestyle)
f. Diabetes-related self-efficacy: 18-item assessment of
confidence to engage in exercise and healthy eating
under different ‘barrier’ conditions (Moore et al., 2011)
g. Depression, anxiety and stress: 21-item Depression,
Anxiety and Stress Scale (DASS-21)
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Figure 1 Participant flow through recruitment process.
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women who received the Croí MyAction intervention to
the control group participants). In the first instance, a
number of numerical and graphical summaries will be used
to summarise the groups at baseline and the within-
participant correlation structure, pre- and post-intervention
. A linear mixed model will be used to compare the change
in mean FPG values across time, adjusting for variables,
such as age and parity, as relevant. Basic statistical analyses
will also be performed to compare data collected from
participants in the intervention arm at the end of the
Croí MyAction programme and at the one-year follow-up
appointment to assess the sustainability of any health
improvements made through participation in the
intervention.
In the case of missing data, an intention-to-treat ana-
lysis will be performed using multiple imputations
(based on 10 imputations) and a predictive model-based
method. In this method, each missing value is replaced
by 10 imputed values, which are generated via random
draws from the Bayesian posterior distributions arisingfrom regression models based on chained equations.
The selection of explanatory variables for inclusion in
the final model will be based on a combination of
clustering, tree-based methods and variable selection
techniques applied to the complete cases and to the
imputed data.
The difference in treatment effect when comparing
those who received the intervention to the control group
participants will be estimated by pooling the results of
each ‘complete model’ (that is, the mean sum of pre-
and post-intervention values, with imputed values added
where necessary) using the Barnard-Rubin adjustment
method. The estimated coefficients, standard errors and
P-values for the intervention-to-control comparison from
both complete and imputed analyses will be reported.
Model checking will be performed using suitable model
diagnostics and residual plots. All statistical analyses will
be performed using the software packages R (version
2.11), R Development Core Team, R Foundation for
Statistical Computing, Vienna, Austria and Minitab 16
Statistical Software, Minitab Inc., Taipei, China.
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Following the RCT, qualitative research will be under-
taken to explore the perceptions, views and experiences
of women who participated in the randomised con-
trolled trial, comparing Croí MyAction participants with
those who followed usual care. This work includes an
exploration of the barriers and facilitators to maintaining
lifestyle changes. Toward this end, semi-structured, one-
to-one interviews will be conducted with 20 participants,
10 from the intervention arm and 10 from the control
arm, within six months of completion of the Croí
MyAction programme. Participants will be purposively
selected to ensure that a representative range of charac-
teristics, such as age and diabetes risk factors at the time
of recruitment, are taken into account. All interviews
will be recorded and transcribed; data analysis will be
based on themes derived from the transcripts. NVivo, a
qualitative software package developed by QSR Inter-
national, Melbourne, Austrlia, will be used to facilitate
data management and analysis.
Economic evaluation
Finally, an economic evaluation, incorporating both cost-
effectiveness analysis and cost-utility analysis, will be
performed to explore the cost-effectiveness of the Croí
MyAction lifestyle modification programme for women
with prior GDM. The economic evaluation will be under-
taken in a manner consistent with the guidelines issued by
the Health and Information Quality Authority in Ireland
[25]. Data will be collected throughout the trial on
resource use and outcome measures; these will provide
the basis for the analysis. Data will be collected via patient
questionnaires on: (a) the costs falling on health and social
care systems, and (b) the costs falling on individuals and
families. Factors that contribute towards health and social
care costs include hospital visits, inpatient stays, GP visits,
medicines and other treatments. Factors that contribute
towards private costs include travel expenses, time input,
and child-minding expenses. Unit costs will be used to
convert data on resource use to costs of care. Incremental
analysis will be used to provide information on the
marginal costs and effects of the programme relative to
standard care through the calculation of incremental
cost-effectiveness ratios. In terms of effectiveness, the
cost-effectiveness analysis will incorporate the primary
and secondary outcomes considered in the trial. In
addition, the cost-utility analysis will consider effective-
ness in terms of Quality Adjusted Life Years (QALYs),
as estimated from patient responses to the EuroQol
EQ-5D measurement tool [26]. Uncertainty in the ana-
lysis will be explored using a combination of univariate
and multivariate sensitivity analyses and decision uncer-
tainty will be presented using cost-effectiveness accept-
ability curves.Trial status
Enrolment into the study started on 14 June 2012.
Recruitment is expected to be complete by March 2013.
Endnotes
a The glucose levels used to diagnose impaired fasting
glucose and impaired glucose tolerance are based on the
2010 recommendations of the American Diabetes
Association and the International Association of Diabetes
and Pregnancy Study Groups (IADPSG) [27].
b The Croí MyAction programme allows for participants
to complete the 12-week curriculum within 16 weeks, thus
accommodating for planned or unplanned events prohibi-
ting participation in a weekly session.
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